Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Illumina, Macrogen; Abbott; GE Healthcare; Cambio, BellBrook Labs

NEW YORK (GenomeWeb News) – Illumina this week said that Macrogen, a Korea-based sequencing services firm, has purchased an additional 10 HiSeq 2000 systems and two MiSeq systems, in addition to upgrades for its HiSeq 2500. Macrogen also intends to develop diagnostic tests based on the MiSeq platform.

Abbott this week announced that the name for its pharmaceutical business, which will be spun off later this year, will be AbbVie. The firm will be headed by Richard Gonazalez, the current head of global pharmaceuticals for Abbott, and will have around $18 billion in annual revenue. Abbott announced the planned split last October.

GE Healthcare has opened a new Fast Track Training Center in Shanghai, China, primarily for its bioprocessing products. However, the firm said that the center also will be stocked with its In Cell and DeltaVision products for cellular screening and Biacore and Microcal tools for protein interaction studies, enabling it to provide training with these products.

Cambio has been named UK distributor for BellBrook Labs' Transcreener High Throughput Screening assays and iuvo Microconduit Array Platform.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.